LOS ANGELES, April 17 (Reuters) - An experimental cancer drug being developed by AstraZeneca Plc (AZN.L: Quote, Profile , Research) failed to show effectiveness against a type of brain cancer in a mid-stage clinical trial, but the results indicate ways to improve the response, researchers said on Tuesday.
